Outcomes of Albumin Use in the Treatment of Acute Hepatorenal Disorders: A Single Center Experience
Main Article Content
Keywords
acute renal failure, albumin, cirrhosis, hepatorenal syndrome, pulmonary edema
Abstract
Intravenous albumin is recommended for hepatorenal disorders (HRD), but individuals who do not recover renal function may beat a high risk for pulmonary edema. We reviewed outcomes by the amount of albumin infused in 93 patients not receiving dialysis at admission but being treated with intravenous albumin for acute HRD at our institution. Absence of renal recovery was defined as no decrease in serum creatinine and requirement of dialysis during hospitalization, and partial renal recovery was defined as a decrease in serum creatinine but not to prehospitalization levels. Associations of clinical factors including total albumin infused, presence of renal recovery, and oliguria with the development of pulmonary edema during hospitalization were determined using logistic regression. Of the 93 patients, 20 patients had complete renal recovery, 17 patients had partial renal recovery, and 56patients showed no renal recovery. Most patients received 300–600 g of albumin. Overall, 47.3% of patients developed pulmonary edema (n=44), but the risk was 75% in patients with oliguria on presentation and no renal recovery versus 17% in those with no oliguria and complete renal recovery (P<0.001). In the logistic regression model, oliguria (3.32; 95% confidence interval [CI]:1.12, 9.81) and no renal recovery (3.38; 95% CI: 1.24, 9.16) were each associated with higher odds of pulmonary edema after adjustment for covariates. No association was noted between total albumin infused and pulmonary edema. In summary, absence of renal recovery and oliguria in patients with HRD receiving intravenous albumin is associated with a higher risk of pulmonary edema.
References
2. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996 Jan;23(1):164–76. http://dx.doi.org/10.1002/hep.510230122
3. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007 Sep;56(9):1310–18.
4. Runyon BA. Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis. 1997;17(3):163–75. http://dx.doi.org/10.1055/s-2007-1007195
5. Romanelli RG, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial. World J Gastroenterol. 2006 Mar;12(9):1403–7. http://dx.doi.org/10.3748/wjg.v12.i9.1403
6. Gines P, Arroyo V. Is there still need for albumin infusions to treat patients with liver disease? Gut. 2000 May;46(5):588–90. http://dx.doi.org/10.1136/gut.46.5.588
7. Boldt J. Use of albumin: An update. Br J Anaesth. 2010 Mar;104(3):276–84. http://dx.doi.org/10.1093/bja/aep393
8. Kumar R, Kumar S, Lata S. Albumin infusion may deleteriously promote extracellular fluid overload without improving circulating hypovolemia in patients of advanced cirrhosis with diabetes mellitus and sepsis. Med Hypotheses. 2013 Apr;80(4):452–5. http://dx.doi.org/10.1016/j.mehy.2012.12.039
9. Peters T Jr. All about albumIn: Biochemistry, genetics, and medical applications. San Diego, CA: Academic Press; 1996.
10. Henriksen JH, Kisza-Kanowitz M, Bendsten F, Moller S. Review article: Volume expansion in patients with cirrhosis. Aliment Pharmacol Ther. 2002;16(Suppl. 5):12–23. http://dx.doi.org/10.1046/j.1365-2036.16.s5.3.x
11. Brinch K, Moller S, Bendtsen F, Becker U, Henriksen J. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol. 2003 Jul;39(1):24–31. http://dx.doi.org/10.1016/S0168-8278(03)00160-0
12. Faloon WW, Eckhardt RD, Murphy L, Cooper AM, Davidson CS. An evaluation of human serum albumin in the treatment of cirrhosis of the liver. J Clin Invest. 1949 Jul;28(4):583–94. http://dx.doi.org/10.1172/JCI102108
13. Nadim K, Kellum J, Davenport A, Wong F, Davis C, Pannu N, et al. Hepatorenal syndrome: The 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012 Feb;16(1):R23. http://dx.doi.org/10.1186/cc11188
14. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009 Jan;361(1):1279–90. http://dx.doi.org/10.1056/NEJMra0809139
15. Sort P, Navasa M, Arroyo V, Aldeguer X, Louvet A, Plessier A, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999 Apr;341(4):403–9. http://dx.doi.org/10.1056/NEJM199908053410603
16. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999 Jun;29(6): 1690–7. http://dx.doi.org/10.1002/hep.510290629
17. Wong F, Pantera L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004 Jul;40(1):55–64. http://dx.doi.org/10.1002/hep.20262
18. Esrailian E, Pantangco ER, Kyulo NL, Hu K-Q, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30 day survival in patients with type I hepatorenal syndrome. Dig Dis Sci. 2007 Mar;52(3):742–48. http://dx.doi.org/10.1007/s10620-006-9312-0
19. Skagen C, Einstein M, Michael RL, Adnan S. Combination treatment with octreotide, midodrine and albumin improves mortality in patients with type I and type II hepatorenal syndrome. J Clin Gastroenterol. 2009 Aug;43(7):680–5. http://dx.doi.org/10.1097/MCG.0b013e318188947c
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.